Douglas Major
Vision Therapy · Paso Robles, CANPI 1386678860
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Alcon at 48.4% of the total. Reporting peaked in 2023 at $316 and has fallen 66.5% since, to $106 in 2025.
Across 14 payments — averaging $77.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$526
- Bausch & Lomb Americas Inc.$118
- Shire North American Group Inc$109
- Dompe US, Inc.$106
- Glaukos Corporation$84
- AbbVie$66
- plus $78 from 2 others
What the payments were for
- Food & beverage$1,087100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $526 |
| Bausch & Lomb Americas Inc. | 1 | $118 |
| Shire North American Group Inc | 1 | $109 |
| Dompe US, Inc. | 1 | $106 |
| Glaukos Corporation | 1 | $84 |
| AbbVie | 1 | $66 |
| Optos, Inc. | 2 | $64 |
| Oyster Point Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ PanOptix$261
- MIEBO$118
- Clareon$114
- XIIDRA$109
- Oxervate$106
How this compares
$1,087 in reported general payments places this provider in the 60th percentile of 47 vision therapy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 59 | $785 |
| Latanoprost | 58 | $472 |
| Prednisolone Acetate | 11 | $343 |
| Timolol Maleate | 16 | $239 |
Paid to pharmacies, not to this prescriber.
Other vision therapy in Paso Robles
- Alan WinkelsteinTemecula$126K
- Beth BallingerNewport Beach$60K
- Gary PolanPacific Palisades$8K
- Leanne LiddicoatRoseville$5K
- Elizabeth YehPacific Palisades$5K
- Brenda CoenCitrus Heights$4K
- Corinna ShelleyTracy$3K
- Dora Szymanowicz NagyRancho Cordova$3K
- Carl HirschWalnut Creek$3K
- Johann SchlagerMerced$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.